Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment.

ABSTRACT:

Background/objectives

The advent of tyrosine kinase inhibitors (TKI), therapeutic antibodies and inducers of apoptosis has revolutionized cancer treatment, yet their application in pediatric tumors, particularly medulloblastoma, remains understudied. Understanding the expression of these targets in specific genetic subgroups could unveil potential repositioning opportunities for already approved drugs.

Methods

We analyzed RNA-sequencing data from the R2 Genomics Analysis and Visualization Platform (N = 763 patients, multiple cohorts) and the TCGA database (six individual cohorts 828 patients) to assess the expression of 73 potential targets of TKIs and antibodies targeting immune checkpoint inhibitors (ICI) or membrane receptors and inducers of apoptosis. These treatments, F

SUBMITTER: Karaulic A 

PROVIDER: S-EPMC12650705 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature